Oncology Studies

A Phase I/II, Multicenter, Open-Label, Multi-Arm Study Evaluating the Safety, Tolerability in Combination with Either Chemotherapy or Venetoclax in the Treatment of Pediatric and Young Adult Patients with Relapsed/Refractory Acute Leukemias or Solid Tumors

Bookmark [insert headline / title here]

A Phase I/II, Multicenter, Open-Label, Multi-Arm Study Evaluating the Safety, Tolerability in Combination with Either Chemotherapy or Venetoclax in the Treatment of Pediatric and Young Adult Patients with Relapsed/Refractory Acute Leukemias or Solid Tumors

More

Phase II Trial of Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma

Bookmark [insert headline / title here]

The purpose of this study is to test the effectiveness of using an investigational agent called DFMO along with etoposide for Neuroblastoma.

More

Phase 1/2 Study of Bempegaldesleukin in Combination with Nivolumab in Children, Adolescents, and Young Adults with Recurrent or Refractory Malignancies (CA045020; PIVOT IO 020)

Bookmark [insert headline / title here]

This is an open-label, sequential-arm, Phase 1b/2 clinical trial of bempegaldesleukin in combination with nivolumab in pediatric participants with malignancies that are refractory, relapsed, or participants for whom curative treatments are lacking.

More

BCC 016 A Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma

Bookmark [insert headline / title here]

This study will evaluate the use of Difluoromethylornithine (DFMO) as a single agent in patients with high risk medulloblastoma after completing therapy as maintenance therapy with the hopes of preventing relapse.

More

A Phase 2b Trial of the MEK 1/2 Inhibitor (MEK) PD-0325901 in Adult and Pediatric Patients with Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) that are Causing Significant Morbidity

Bookmark [insert headline / title here]

A Phase 2b Trial of the MEK 1/2 Inhibitor (MEK) PD-0325901 in Adult and Pediatric Patients with Neurofibromatosis Type 1 (NF1)-Associated Inoperable Plexiform Neurofibromas (PNs) that are Causing Significant Morbidity

More

An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)

Bookmark [insert headline / title here]

Treatment of cHL in children and young adults – evaluation of pembrolizumab in a subgroup with inadequate early response to frontline chemotherapy.

More